glp 1 support DietWorks GLP-1 Companion 1 Support helps support appetite control GLP Support System - IDLife

How do GLP-1 drugs work to combat obesity

According to FDA labeling for Wegovy (semaglutide 2.4 mg), patients should be evaluated after 12 weeks at the maintenance dose, and discontinuation considered if less than 5% weight loss has been achieved

As part of our commitment to delivering individualized care, our healthcare professionals will assess your eligibility for a Semaglutide GLP-1 prescription based on specific criteria outlined by regulatory authorities and medical guidelines

Our findings indicate that patients treated with semaglutide, particularly at higher doses such as Wegovy (2.4 mg), exhibited a higher incidence of psychiatric outcomes compared to non-GLP-1 RA users

doi:10.3389/fncel.2023.1156829 9